The 100-year anniversary of the first experimental apheresis performed by John Abel on uremic dogs in 1914 provides the opportunity for discussion on the current state of classic apheresis as well as technological progress and clinical experiences with its new options presented in the world literature in the last 15 years, such as the following: double filtration, plasma adsorption and immunoadsorption, leuko- and cytapheresis and low-density lipoprotein apheresis. In our review, we highlight the potential limitations for further development of those highly promising techniques, such as the following: the lack of multicenter, controlled clinical studies; insufficient knowledge of the mechanisms of those techniques and last but not least, the restricted access to apheresis, caused both by high expenditure and organizational negligence, even in highly developed countries. Special attention was paid to the most recent recommendations by the American Society of Apheresis in primary and secondary renal diseases, which are the subject of our professional interest.

Keywords:
Plasmapheresis, Cryofiltration, LDL apheresis, Therapeutic plasma exchange, Immunoadsorption, American Society of Apheresis
1.
Yokoyama H, Wada T, Furuichi K: Immunomodulation effects and clinical evidence of apheresis in renal diseases. Ther Apher Dial 2003;7:513-519.
2.
Kenneth H, Sumak M, Gail A: Therapeutic plasma exchange. N Engl J Med 1984;22:762-768.
3.
Lockwood CM, Boulton-Jones JM, Lowenthal RM, et al: Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2:252-254.
4.
Kaplan AA: Apheresis for renal disease. Ther Apher 2001;5:134-141.
5.
Wańkowicz Z, Tymowicz J, Korsak J: [Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis]. Pol Merkur Lekarski 1998;5:304-306.
6.
Yokoyama H, Wada T, Zhang W, et al: Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol 2007;11:122-127.
7.
Agishi T: Birth of the concept and the development of extracorporeal immunomodulation. Ther Apher 2002;6:312-316.
8.
McLeod BC: Apheresis: Priciples and Practice, ed 2. AABB Press, 2003.
9.
Brecher ME: Plasma exchange: why we do what we do. J Clin Apher 2002;17:207-211.
10.
Brecher ME: Technical Manual, ed 1. AABB Press, 2005.
11.
McLeod BC, Triluzi DJ: Therapeutic Apheresis: A Physician's Handbook, ed 1. AABB Press, 2005.
12.
Galel SA, Nguyen DD, Fontaine MJ, et al: Transfusion medicine. Therapeutic Apheresis; in Greer JP, Foerster J, Rodgers G (eds): Wintrobe's Clinical Hematology. Lippincolt Williams & Wilkins, 2008, pp 711-712.
13.
Theunissen K, Bracke T, Berckmans D, et al: Birth of a new generation of therapeutic apheresis platforms: interim analysis of a routine use experience with the spectra optia. J Clin Apher 2007;22:69.
14.
Lefevre PA, Poullin P: Therapeutic plasma exchange with the new continous blood flow separator spectra optia. J Clin Apher 2008;23:43-48.
15.
Siami GA, Siami FS: Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher 2001;5:315-320.
16.
Siami GA, Siami FS: Current topics on cryofiltration technologies. Ther Apher 2001;5:283-286.
17.
Deodhar A, Allen E, Daoud K, et al: Vasculitis secondary to staphylococcal protein A immunoadsorption (Prosorba column) treatment in rheumatoid arthritis. Semin Arthritis Rheum 2002;32:3-9.
18.
Iglesias J, D'Agati VD, Levine JS: Acute glomerulonephritis occurring during immunoadsorption with staphylococcal protein A column (Prosorba). Nephrol Dial Transplant 2004;19:3155-3159.
19.
Ronco C, Brendolan A, Lonnemann G, et al: A pilot study of coupled plasma filtration with adsoption in septic shock. Crit Care Med 2002;30:1250-1255.
20.
Berlot G, Tomasini A, Agbedjro A: Coupled plasma filtration - adsoption; in Vincent JL (ed): Annual Update in Intensive Care and Emergency Medicine. Springer-Verlag, 2012, pp 653-658.
21.
Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361:62-72.
22.
McLeod B, Sniecinski I, Ciavarella D: Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999;39:282-288.
23.
McLeod BC, Price TH, Weinstein R (eds): Apheresis: Principles and Practice. Bethesda, AABB Press, 2003, pp 268-272.
24.
Millwad PA, Bandarenko N, Brecher ME: Thrapeutic apheresis basic principles and practical aspects; in Hillyer CD, Silberstein LE, Ness PM (eds): Blood Banking and Transfusion Medicine: Basic Principles and Practice. Churchill Livingstone Elsevier, 2007, pp 727-736.
25.
Nakanishi T, Suzuki N, Kuragano T, et al: Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 2014;18:41-49.
26.
Szczepiorkowski ZM, Shaz BH, Bandarenko N, et al: The new approach to assignment of ASFA categories - introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007;22:96-105.
27.
Guyatt GH, Cook DJ, Jaeschke R, et al: Grades of recommendation for antithrombotic agents: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):123S-131S.
28.
Schwartz J, Winters JL, Padmanabhan A, et al: Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145-284.
29.
Shaz BH, Schwartz J, Winters JL: How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures. Transfusion 2014;54:17-25.
30.
Szczepiorkowski ZM, Winters JL, Bandarenko N, et al: Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the American Society for Apheresis. J Clin Apher 2010;25:83-177.
31.
McLeod BC: An approach to evidence-based therapeutic apheresis. J Clin Apher 2002;17:124-132.
32.
Wańkowicz Z: The role of technological progress vs. accidental discoveries and clinical experience. Med Sci Monit 2013;19:984-992.
33.
Stenvinkel P, Alvestrand A, Angelin B, et al: LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excertion. Eur J Clin Invest 2000;30:866-870.
34.
Haas M, Böhmig GA, Leko-Mohr Z, et al: Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002;17:1503-1508.
35.
Sułowicz W, Stompór T: LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant 2003;18(suppl 5):v59-v62.
36.
Yamagata K, Hirayama K, Mase K, et al: Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN. J Clin Apher 2005;20:244-251.
37.
Yokoyama H, Wada T, Zhang W, et al: Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol 2007;11:122-127.
38.
Sanchez AP, Ward DM: Therapeutic apheresis for renal disorders. Semin Dial 2012;25:119-131.
39.
Miyata H, Uno K, Ono T, et al: Low density lipoprotein apheresis ameliorates interferon-γ production in patients with nephrotic syndrome. Ther Apher Dial 2012;16:189-194.
40.
Hickstein H, Koball S, Lehmann R, et al: ABO incompatible kidney transplantation using unspecific immunoadsorption. Transfus Apher Sci 2014;50:263-266.
41.
Kobayashi S, Tamura N, Tsuda H, et al: Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis 1992;51:399-401.
42.
Abel JJ, Rowntree LG, Turner BB: Plasma removal with return of corpuscles (plasmaphaeresis): first paper. J Pharmacol Exp Ther 1914;5:625-641.
43.
Reeves HM, Winters JL: The mechanisms of action of plasma exchange. Br J Haematol 2014;164:342-351.
44.
Cybulsky AV, Walsh M, Knoll G, et al: Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults. Am J Kidney Dis 2014;63:363-377.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.